Pricing Log in Create free account

Keros Therapeutics, Inc. (KROS) vs Entrada Therapeutics, Inc. (TRDA)

Keros Therapeutics, Inc. and Entrada Therapeutics, Inc. are both Biotechnology companies. Keros Therapeutics, Inc. and Entrada Therapeutics, Inc. are of similar size ($191.5M and $183.7M). Keros Therapeutics, Inc. grew revenue faster over the last twelve months: −76.4% against −93.5%. Keros Therapeutics, Inc. has the higher net margin (−112.2% vs −4,058.0%) and the higher return on invested capital (−233.2% vs −2,009.0%). Across the 15 metrics below, Keros Therapeutics, Inc. leads on 15 and Entrada Therapeutics, Inc. on 0.

Valuation

Metric KROS TRDA Biotechnology median
P/E n/m n/m 10.60
P/S 3.38 52.10 9.40
P/B 0.67 1.04 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 1.02 n/m 0.66
EV/Sales (1.33) 3.57 9.02
Earnings yield (30.02%) (78.53%) (32.88%)
Free cash flow yield (25.93%) (65.80%) (23.13%)

Profitability

Metric KROS TRDA Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (133.16%) (4,303.82%) 0.00%
Net margin (112.18%) (4,057.98%) 0.00%
Free cash flow margin (87.73%) (3,428.06%) 0.00%
Return on equity (12.56%) (59.88%) (51.96%)
Return on assets (11.76%) (47.48%) (46.06%)
Return on invested capital (233.22%) (2,008.96%) 0.00%

Growth

Metric KROS TRDA Biotechnology median
Revenue growth (TTM) (76.37%) (93.54%) 6.76%
EPS growth (last fiscal year) 146.00% (306.55%) 29.88%
Revenue growth, 5-year CAGR 89.45% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KROS TRDA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 18.14 7.85 4.97
Net debt to EBITDA (4.16) 1.88 1.01

Dividend

Metric KROS TRDA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KROS TRDA Biotechnology median
Market cap 183.68m 191.45m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack